Personalis (NASDAQ:PSNL) Posts Earnings Results, Misses Expectations By $0.05 EPS

Personalis (NASDAQ:PSNL) released its quarterly earnings results on Tuesday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.05), FiscalAI reports. The firm had revenue of $22.36 million for the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%.

Personalis Stock Up 2.4%

Personalis stock traded up $0.32 during mid-day trading on Tuesday, reaching $13.52. 1,677,899 shares of the company were exchanged, compared to its average volume of 5,263,449. Personalis has a twelve month low of $3.84 and a twelve month high of $16.39. The firm’s 50-day simple moving average is $12.12 and its two-hundred day simple moving average is $9.22.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on PSNL shares. BTIG Research increased their target price on Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a research note on Monday, July 20th. TD Cowen reiterated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Morgan Stanley boosted their price target on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th. Finally, Needham & Company LLC cut Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Personalis currently has a consensus rating of “Hold” and a consensus price target of $14.25.

Insider Buying and Selling at Personalis

In other Personalis news, CFO Aaron Tachibana sold 51,251 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,620,618.94. The trade was a 20.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $3,103,215.90. This trade represents a 29.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock worth $5,599,929 over the last three months. 4.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Personalis

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in shares of Personalis during the second quarter worth $30,000. Caitong International Asset Management Co. Ltd lifted its position in Personalis by 184.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after buying an additional 3,592 shares during the period. BNP Paribas Financial Markets lifted its position in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the period. AQR Capital Management LLC acquired a new stake in Personalis in the 4th quarter worth about $82,000. Finally, DRW Securities LLC acquired a new stake in Personalis in the 4th quarter worth about $83,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.